X

Trial Profile

A Phase 2, Open-Label Randomized Trial Evaluating the Efficacy and Safety of Two Dosages of Once Daily Oral CA-170 in Patients with Selected Relapsed Advanced Tumors (ASIAD)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CA 170 (Primary)
Indications Head and neck cancer; Hodgkin's disease; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Therapeutic Use
Sponsors Aurigene Oncology

Most Recent Events

10 Jan 2020 Status changed from recruiting to discontinued.
07 Nov 2018 According to a Curis media release, data from this trial will be presented at the 33rd Society for Immunotherapy of Cancer Annual Meeting
02 Aug 2018 According to a Curis media release, Aurigene is continuing patient enrolment at select sites in India, additional updates are expected in 2H 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com